Barclays lowered the firm’s price target on Cytokinetics (CYTK) to $53 from $55 and keeps an Overweight rating on the shares following the Q1 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Receives Buy Rating Amid Positive Outlook for Aficamten and Strong Financial Position
- Cytokinetics’ Earnings Call: Balancing Progress and Challenges
- Cytokinetics Buy Rating: Strategic Developments and Market Opportunities Drive Optimism Despite FDA Delay
- Cytokinetics: Strong Financials and Promising Pipeline Drive Buy Rating
- Cytokinetics price target lowered to $80 from $86 at Citi